Bee-Cheng Sim

Bee-Cheng Sim has a diverse work experience spanning over two decades. They began their career at The Scripps Research Institute as a Postdoctoral Fellow, focusing on the role of the T-cell receptor in disease susceptibility. Following this, they joined Vertex Pharmaceuticals as a Senior Scientist, leading ultra-high throughput screening campaigns in immuno-suppression and neurodegenerative diseases.

Sim then moved on to Ambrx, where they held two positions. As an Associate Director in New Product Initiative, they focused on target selection through due diligence and forming consultant panels across various therapeutic areas. They also outlined project scope and target product profiles. In their role as Associate Director in Biological Sciences, they were responsible for leading cell-based and bioanalytical assay development efforts, with expertise in PEGylated proteins and site-directed antibody-based therapeutics.

Currently, Sim holds a leadership position at Amunix as the Director to Vice President of Discovery Biology & Preclinical Development. In this role, they provide strategic direction and oversight for programs focused on CD3 bispecific T-cell recruiters, antibody-based drug conjugates, and half-life extension of therapeutics. They have expertise in stage-appropriate cell-based and bioanalytical assays, in vivo pharmacokinetics and pharmacology studies, non-human primate toxicology studies, and GMP-related potency assays. They are also skilled in target selection due diligence and review.

Bee-Cheng Sim studied immunology at Scripps Research from 1993 to 1998. No degree information is specified.